Citation:Sternfeld A,Ehrlich R,Weinberger D,Dotan A.Effect of different lens status on intraocular pressure elevation in patients treated with anti-vascular endothelial growth factor injections.Int J Ophthalmol 2020;13(1):79-84,doi:10.18240/ijo.2020.01.12
Effect of different lens status on intraocular pressure elevation in patients treated with anti-vascular endothelial growth factor injections
Received:November 08, 2018  Revised:July 11, 2019
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2020.01.12
Key Words:anti-VEGF injections  cataract surgery  intraocular pressure  Nd:YAG capsulotomy
Fund Project:
           
AuthorInstitution
Amir Sternfeld Department of Ophthalmology, Rabin Medical Center Beilinson Hospital, Petach Tikva 2, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 1, Israel
Rita Ehrlich Department of Ophthalmology, Rabin Medical Center Beilinson Hospital, Petach Tikva 2, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 1, Israel
Dov Weinberger Department of Ophthalmology, Rabin Medical Center Beilinson Hospital, Petach Tikva 2, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 1, Israel
Assaf Dotan Department of Ophthalmology, Rabin Medical Center Beilinson Hospital, Petach Tikva 2, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 1, Israel
Hits: 334
Download times: 73
Abstract:
      AIM: To assess the effect of lens status on sustained intraocular pressure (IOP) elevation in patients treated intravitreally with anti-vascular endothelial growth factor (VEGF) agents.

    METHODS: Data were retrospectively collected for all patients treated with intravitreal injections of anti-VEGF medication at a tertiary medical center in July 2015. Findings were analyzed by lens status during 6 months’ follow-up. The main outcome measure was a sustained increase in IOP (≥21 mm Hg or change of ≥6 mm Hg from baseline on ≥2 consecutive visits, or addition of a new IOP-lowering medication during follow-up).

    RESULTS: A total of 119 eyes of 100 patients met the study criteria: 40 phakic, 40 pseudophakic, and 39 pseudophakic after Nd:YAG capsulotomy. The rate of sustained IOP elevation was significantly higher in the post-capsulotomy group (23.1%) than in the phakic/pseudophakic groups (8.1%; P=0.032), with no statistically significant differences among the 3 groups in mean number of injections, either total (P=0.82) or by type of anti-VEGF mediation (bevacizumab: P=0.19; ranibizumab: P=0.13), or mean follow-up time (P=0.70).

    CONCLUSION: Nd:YAG capsulotomy appears to be a risk factor for sustained IOP elevation in patients receiving intravitreal anti-VEGF injections. This finding has important implications given the growing use of anti-VEGF treatment and the irreversible effects of elevated IOP.

PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942959/
Supplementary Material
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment